Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone908-947-3120
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.86 billion
Profitability
Miscellaneous
Employees6,000
Next Earnings Date2/26/2020 (Confirmed)
OptionableOptionable
Amneal Pharmaceuticals (NYSE:AMRX) Frequently Asked Questions
What is Amneal Pharmaceuticals' stock symbol?
Amneal Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "AMRX."
How were Amneal Pharmaceuticals' earnings last quarter?
Amneal Pharmaceuticals Inc (NYSE:AMRX) announced its earnings results on Wednesday, February, 26th. The company reported $0.08 earnings per share for the quarter, beating analysts' consensus estimates of $0.03 by $0.05. The firm had revenue of $397 million for the quarter, compared to analyst estimates of $382.10 million. Amneal Pharmaceuticals had a negative net margin of 19.61% and a positive return on equity of 23.17%. The company's revenue for the quarter was down 20.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.33 EPS. View Amneal Pharmaceuticals' Earnings History.
When is Amneal Pharmaceuticals' next earnings date?
What guidance has Amneal Pharmaceuticals issued on next quarter's earnings?
Amneal Pharmaceuticals updated its FY20 earnings guidance on Wednesday, February, 26th. The company provided EPS guidance of 0.45-0.60 for the period, compared to the Thomson Reuters consensus estimate of $0.52. The company issued revenue guidance of 1.875-1.975 billion, compared to the consensus revenue estimate of $1.68 billion.
What price target have analysts set for AMRX?
12 brokers have issued 12 month target prices for Amneal Pharmaceuticals' stock. Their forecasts range from $2.50 to $14.00. On average, they expect Amneal Pharmaceuticals' stock price to reach $6.30 in the next year. This suggests a possible upside of 63.6% from the stock's current price. View Analyst Price Targets for Amneal Pharmaceuticals.
What is the consensus analysts' recommendation for Amneal Pharmaceuticals?
12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amneal Pharmaceuticals in the last year. There are currently 2 sell ratings, 6 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Amneal Pharmaceuticals.
What are Wall Street analysts saying about Amneal Pharmaceuticals stock?
Here are some recent quotes from research analysts about Amneal Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Amneal Pharmaceuticals LLC is an integrated specialty pharmaceutical company. It focused on developing, manufacturing and distributing generic, brand and biosimilar products. The company operates primarily in North America, Asia and Europe. Amneal Pharmaceuticals LLC, formerly known as Impax Laboratories Inc., is based in New Jersey, United States. " (2/11/2020)
- 2. Cantor Fitzgerald analysts commented, ". We reiterate our OW rating and 12-month PT of $35 for AMRX shares post a 4Q18 beat and despite lower than anticipated guidance for 2019. We still believe that AMRX will be able to successfully grow from a mid-size generics company into a leading generics and specialty pharma company. Therefore, upward earnings revisions in 2020+ should drive the stock higher. These upward earnings revisions should come from: 1) new generic drug launches, 2) operating margin expansion, 3) high-margin brand drug sales, and 4) strategic M&A as well as tuck-in deals." (2/28/2019)
Has Amneal Pharmaceuticals been receiving favorable news coverage?
Media stories about AMRX stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Amneal Pharmaceuticals earned a coverage optimism score of 2.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Amneal Pharmaceuticals.
Are investors shorting Amneal Pharmaceuticals?
Amneal Pharmaceuticals saw a decrease in short interest in the month of February. As of February 14th, there was short interest totalling 3,940,000 shares, a decrease of 27.3% from the January 30th total of 5,420,000 shares. Based on an average trading volume of 2,810,000 shares, the short-interest ratio is presently 1.4 days. Approximately 4.8% of the company's stock are sold short. View Amneal Pharmaceuticals' Current Options Chain.
Who are some of Amneal Pharmaceuticals' key competitors?
Some companies that are related to Amneal Pharmaceuticals include United Therapeutics (UTHR), BridgeBio Pharma (BBIO), Global Blood Therapeutics (GBT), Nektar Therapeutics (NKTR), FibroGen (FGEN), GW Pharmaceuticals PLC- (GWPH), Arrowhead Pharmaceuticals (ARWR), Evotec (EVTCY), Mirati Therapeutics (MRTX), PTC Therapeutics (PTCT), SAGE Therapeutics (SAGE), HUTCHISON CHINA/S (HCM), Agios Pharmaceuticals (AGIO), PPD (SDGR) and Zai Lab (ZLAB).
What other stocks do shareholders of Amneal Pharmaceuticals own?
Who are Amneal Pharmaceuticals' key executives?
Amneal Pharmaceuticals' management team includes the folowing people:
- Mr. Paul M. Bisaro, Exec. Chairman (Age 58)
- Mr. Chirag K. Patel, Co-Founder & Co-Chairman (Age 52)
- Mr. Chintu Patel, Co-Founder & Co-Chairman (Age 47)
- Mr. Robert A. Stewart, Pres, CEO & Director (Age 51)
- Ms. Nikita Shah, Sr. VP & Chief HR Officer (Age 41)
Who are Amneal Pharmaceuticals' major shareholders?
Amneal Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include State Street Corp (0.76%), Geode Capital Management LLC (0.51%), Bank of New York Mellon Corp (0.44%), Prudential Financial Inc. (0.31%), Mackay Shields LLC (0.26%) and Bank of America Corp DE (0.24%). Company insiders that own Amneal Pharmaceuticals stock include Andrew S Boyer, Bryan M Reasons, International Ltd Fosun, Joseph Todisco, Nikita Shah, Paul Bisaro, Peter R Terreri, Pradeep Bhadauria and Ted C Nark. View Institutional Ownership Trends for Amneal Pharmaceuticals.
Which institutional investors are selling Amneal Pharmaceuticals stock?
AMRX stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Spark Investment Management LLC, Strs Ohio, First Trust Advisors LP, Cubist Systematic Strategies LLC, Goldman Sachs Group Inc., UBS Asset Management Americas Inc. and Meeder Asset Management Inc.. View Insider Buying and Selling for Amneal Pharmaceuticals.
Which institutional investors are buying Amneal Pharmaceuticals stock?
AMRX stock was purchased by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Mackay Shields LLC, Marshall Wace LLP, Bank of America Corp DE, State Street Corp, Geode Capital Management LLC, Panagora Asset Management Inc. and Alambic Investment Management L.P.. Company insiders that have bought Amneal Pharmaceuticals stock in the last two years include Andrew S Boyer, International Ltd Fosun, Joseph Todisco, Paul Bisaro, Pradeep Bhadauria and Ted C Nark. View Insider Buying and Selling for Amneal Pharmaceuticals.
How do I buy shares of Amneal Pharmaceuticals?
Shares of AMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Amneal Pharmaceuticals' stock price today?
One share of AMRX stock can currently be purchased for approximately $3.85.
How big of a company is Amneal Pharmaceuticals?
Amneal Pharmaceuticals has a market capitalization of $1.15 billion and generates $1.86 billion in revenue each year. The company earns $-169,730,000.00 in net income (profit) each year or $0.95 on an earnings per share basis. Amneal Pharmaceuticals employs 6,000 workers across the globe.View Additional Information About Amneal Pharmaceuticals.
What is Amneal Pharmaceuticals' official website?
How can I contact Amneal Pharmaceuticals?
Amneal Pharmaceuticals' mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The company can be reached via phone at 908-947-3120 or via email at [email protected]
MarketBeat Community Rating for Amneal Pharmaceuticals (NYSE AMRX)
MarketBeat's community ratings are surveys of what our community members think about Amneal Pharmaceuticals and other stocks. Vote "Outperform" if you believe AMRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
